Mineralys Therapeutics: Therapeutic Approach Confirmed by AstraZeneca Data

Mineralys Therapeutics is a biotechnology company based in Pennsylvania that develops new therapies for hypertension and related conditions such as kidney diseases or sleep apnea. At the center of its approach is the drug Lorundrostat, an oral inhibitor of aldosterone synthase, which has shown significant reductions in systolic blood pressure in clinical trials. With this strategy, Mineralys aims to tackle disease-causing mechanisms at their root and thereby create options for patients that go beyond standard therapies. The recent capital increase...